Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Equity Ratio (2016 - 2025)

Lipocine (LPCN) has disclosed Equity Ratio for 13 consecutive years, with 0.88 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio fell 4.74% year-over-year to 0.88, compared with a TTM value of 0.88 through Sep 2025, down 4.74%, and an annual FY2024 reading of 0.93, up 5.33% over the prior year.
  • Equity Ratio was 0.88 for Q3 2025 at Lipocine, down from 0.92 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.95 in Q3 2022 and bottomed at 0.76 in Q2 2021.
  • Average Equity Ratio over 5 years is 0.9, with a median of 0.92 recorded in 2025.
  • The sharpest move saw Equity Ratio skyrocketed 168.51% in 2021, then dropped 6.7% in 2023.
  • Year by year, Equity Ratio stood at 0.87 in 2021, then grew by 9.32% to 0.95 in 2022, then fell by 6.7% to 0.89 in 2023, then increased by 5.33% to 0.93 in 2024, then dropped by 5.67% to 0.88 in 2025.
  • Business Quant data shows Equity Ratio for LPCN at 0.88 in Q3 2025, 0.92 in Q2 2025, and 0.94 in Q1 2025.